-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Kangyuan Pharmaceutical submitted a new drug clinical application for Jiuwei Shufeng Pingchuan Granules
.
It is understood that this is the 37th class 1 new medicine declared for proprietary Chinese medicine this year
.
In addition, it is worth mentioning that Yiling Pharmaceutical's Yishen Yangxin Anshen Tablets and Huakang Pharmaceutical's Yiqi Tongqiao Pills have also been approved some time ago
.
Among them, Yishen Yangxin Anshen Tablets can be used for the treatment of insomnia syndromes of heart-blood deficiency and insufficient kidney essence
.
The new Chinese medicine is on the market, providing a new treatment option for patients with insomnia
.
The Yiqi Tongqiao Pills can be used for the treatment of seasonal allergic rhinitis with the syndrome of lung and spleen qi deficiency in traditional Chinese medicine.
It is suitable for patients with seasonal allergic rhinitis
.
Regarding the continuous increase in the number of clinical applications and listings of new Chinese medicines, the industry believes that it is the result of China's traditional Chinese medicine industry vigorously promoting innovative development
.
It is understood that the traditional Chinese medicine market in China has always had problems such as large and fragmented production enterprises, serious product homogeneity, and lack of core competitiveness
.
According to statistics, from 2015 to 2020, only 10 new Chinese medicines were approved in China
.
In this context, in order to encourage the innovation and development of traditional Chinese medicine, a series of documents have been issued from the state to the local level in recent years
.
For example, in September 2020, the State Food and Drug Administration issued the "Registration Classification and Application Data Requirements for Traditional Chinese Medicines", which broadened the scope of improved new drugs and encouraged the secondary development of traditional Chinese medicines
.
In December 2020, the National Medical Products Administration issued the "Implementation Opinions on Promoting the Inheritance, Innovation and Development of Traditional Chinese Medicines", which clearly put forward 20 reform measures including promoting the integrity and innovation of traditional Chinese medicines and improving the review and approval system in line with the characteristics of traditional Chinese medicines
.
Among them, it is mentioned again that it will promote the development of ancient classic Chinese medicine compound preparations, and promote the innovative development and secondary development of Chinese medicine
.
At present, with the help of a series of policies, the application of new Chinese patent medicines in Class 1 has also begun to show a surge: in 2020, 5 products have been declared for marketing, 9 products have been declared for clinical use, and 7 products have been declared since 2021.
On the market, 30 products are applied for clinical application
.
In addition, in addition to the substantial increase in the approval of new Chinese medicines, from the perspective of the approved and declared Chinese patent medicines in recent years, leading Chinese patent medicine companies such as Tasly, Yiling Pharmaceutical, Kangyuan Pharmaceutical, etc.
continue to accelerate the development of new drugs At the same time, it is also making breakthroughs in the product line from the perspective of the enterprise itself
.
For example, Huiren Pharmaceuticals has always attached great importance to R&D and innovation.
Currently, it is driven by R&D and design and spares no effort to increase R&D investment
.
This year, Huiren Pharmaceutical's construction of the Nanchang R&D platform, which is nearing completion, is another important measure following the Shanghai R&D base
.
In addition, according to relevant staff, in the future strategy, Huiren will also plan to continue to advance from 13 high-quality dimensions such as brand reputation, perceived quality, product experience, high-quality cultural construction, and service quality.
, And gradually improve to achieve high-quality goals
.
The industry predicts that with the continuous promotion of the Chinese medicine innovation policy and the continuous improvement of the R&D strength of domestic pharmaceutical companies, the era of the outbreak of innovative Chinese medicine drugs is coming
.
.
It is understood that this is the 37th class 1 new medicine declared for proprietary Chinese medicine this year
.
In addition, it is worth mentioning that Yiling Pharmaceutical's Yishen Yangxin Anshen Tablets and Huakang Pharmaceutical's Yiqi Tongqiao Pills have also been approved some time ago
.
Among them, Yishen Yangxin Anshen Tablets can be used for the treatment of insomnia syndromes of heart-blood deficiency and insufficient kidney essence
.
The new Chinese medicine is on the market, providing a new treatment option for patients with insomnia
.
The Yiqi Tongqiao Pills can be used for the treatment of seasonal allergic rhinitis with the syndrome of lung and spleen qi deficiency in traditional Chinese medicine.
It is suitable for patients with seasonal allergic rhinitis
.
Regarding the continuous increase in the number of clinical applications and listings of new Chinese medicines, the industry believes that it is the result of China's traditional Chinese medicine industry vigorously promoting innovative development
.
It is understood that the traditional Chinese medicine market in China has always had problems such as large and fragmented production enterprises, serious product homogeneity, and lack of core competitiveness
.
According to statistics, from 2015 to 2020, only 10 new Chinese medicines were approved in China
.
In this context, in order to encourage the innovation and development of traditional Chinese medicine, a series of documents have been issued from the state to the local level in recent years
.
For example, in September 2020, the State Food and Drug Administration issued the "Registration Classification and Application Data Requirements for Traditional Chinese Medicines", which broadened the scope of improved new drugs and encouraged the secondary development of traditional Chinese medicines
.
In December 2020, the National Medical Products Administration issued the "Implementation Opinions on Promoting the Inheritance, Innovation and Development of Traditional Chinese Medicines", which clearly put forward 20 reform measures including promoting the integrity and innovation of traditional Chinese medicines and improving the review and approval system in line with the characteristics of traditional Chinese medicines
.
Among them, it is mentioned again that it will promote the development of ancient classic Chinese medicine compound preparations, and promote the innovative development and secondary development of Chinese medicine
.
At present, with the help of a series of policies, the application of new Chinese patent medicines in Class 1 has also begun to show a surge: in 2020, 5 products have been declared for marketing, 9 products have been declared for clinical use, and 7 products have been declared since 2021.
On the market, 30 products are applied for clinical application
.
In addition, in addition to the substantial increase in the approval of new Chinese medicines, from the perspective of the approved and declared Chinese patent medicines in recent years, leading Chinese patent medicine companies such as Tasly, Yiling Pharmaceutical, Kangyuan Pharmaceutical, etc.
continue to accelerate the development of new drugs At the same time, it is also making breakthroughs in the product line from the perspective of the enterprise itself
.
For example, Huiren Pharmaceuticals has always attached great importance to R&D and innovation.
Currently, it is driven by R&D and design and spares no effort to increase R&D investment
.
This year, Huiren Pharmaceutical's construction of the Nanchang R&D platform, which is nearing completion, is another important measure following the Shanghai R&D base
.
In addition, according to relevant staff, in the future strategy, Huiren will also plan to continue to advance from 13 high-quality dimensions such as brand reputation, perceived quality, product experience, high-quality cultural construction, and service quality.
, And gradually improve to achieve high-quality goals
.
The industry predicts that with the continuous promotion of the Chinese medicine innovation policy and the continuous improvement of the R&D strength of domestic pharmaceutical companies, the era of the outbreak of innovative Chinese medicine drugs is coming
.
